Bli medlem
Bli medlem

Du är här

2022-11-10

Nomination Committee for Nanexa AB (publ) Annual General Meeting 2023

The Nomination Committee has been appointed in Nanexa AB (publ) for the Annual General Meeting 2023 in accordance with the principles adopted by Nanexa’s Annual General Meeting on 9 June 2022.

The members of the Nomination Committee are appointed by the three largest shareholders in the company by votes as of 30 September 2022. In the event that one of the three largest shareholders does not wish to appoint a member, the fourth largest shareholder shall be asked and so on until the Nomination Committee consists of three members. The Chairman of the Board of Directors shall be adjunct member of the Nomination Committee.

For 2023, there have been no changes in the proposals for members, and the members of the Nomination Committee are therefore:

  • Philip Norin
  • Hanno Lindroth, appointed by Mårten Rooth
  • Christian Östberg, appointed by Anders Johansson
  • Göran Ando, Chairman of the Board, adjunct

The Nomination Committee's proposals are presented in the notice of the 2023 Annual General Meeting and on the company's website, www.nanexa.com.

Shareholders may contact the Nomination Committee with suggestions regarding its work by sending e-mail to info@nanexa.se (heading "Nanexa's Nomination Committee") or by letter to: Nanexa AB, Attn: Nanexa's Nomination Committee, Virdings Allé 2, SE-754 50, Uppsala, Sweden. The date of the 2023 Annual General Meeting and the latest date for submitting proposals to the Nomination Committee will be announced on Nanexa's website before the end of 2022.

For additional information, please contact:


David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
Erik Penser Bank is the company’s Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)


Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments


Nomination Committee for Nanexa AB (publ) Annual General Meeting 2023

Författare MFN